AdvanDx

AdvanDx is a prominent player in the biotechnology, healthcare, and medical devices industries, specializing in rapid and accurate molecular diagnostic tests for identifying pathogens causing critical infections in hospitalized patients. Founded in 2002 and headquartered in the United States, AdvanDx is dedicated to improving antibiotic decision-making, patient outcomes, and reducing unnecessary antibiotic use and costs. The company's unique approach, Whole Cell Analysis (WCA), utilizes its proprietary Peptide Nucleic Acid Fluorescence In Situ Hybridization (PNA FISH) technology platform. This technology enables fast and highly accurate single cell analysis for bacterial species identification in patient samples with critical infections. AdvanDx is a market leader in molecular testing of positive blood cultures, allowing clinical microbiology labs to provide pathogen identification results 48 to 72 hours earlier than conventional testing methods. AdvanDx's PNA FISH® tests have demonstrated their significance in clinical studies by reducing patient mortality, shortening the length of stay, and lowering hospital costs through ensuring early, appropriate antibiotic therapy for patients with bloodstream infections (septicemia). The company secured a Debt Financing investment on 17th March 2015, showcasing investor confidence in its innovative solutions for improving patient care and healthcare system efficiency.